The Nervous System Damage in Covid-19 Patients

Белопасов, В. В.; Samoilova, E. M.; Baklaushev, V. P.

doi:10.17816/clinpract34851

Cited by 50 publications

(21 citation statements)

References 206 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…COVID-19 может провоцировать развитие и ухудшать течение сердечно-сосудистых болезней и ЦВЗ [39][40][41][42][43]. У пациентов с ХИГМ после перенесенной новой коронавирусной инфекции может наблюдаться прогрессирование сосудистого поражения головного мозга, развитие инсультов.…”

Section: Distribution Of Patients In Accordance With the Improvement unclassified

The role of the new coronavirus infection (COVID-19) in the progression and development of cerebrovascular diseases. A competent choice of pathogenic treatment is the key to success in treatment and prevention. An expert’s view from the ‘red zone’

Ковальчук¹

2021

RJTAO

View full text Add to dashboard Cite

COVID-19 worsens the course of cerebrovascular diseases (CVD), including chronic cerebral ischaemia (CCI). The Actovegin drug, which has long been widely used in CCI treatment, has an antioxidant and endothelium protective effect. It makes sense to study the effect of Actovegin therapy on the clinical manifestations of CCI in patients with a recent experience of COVID-19.Objective: to evaluate Actovegin efficacy in the treatment of CCI in patients with a recent experience of COVID-19.Patients and methods. The study included 440 patients (234 female; 206 male) with a recent experience of COVID-19, suffering from CCI, their average age being 67.8 years (from 54 to 85 years). All patients were broken down into two groups of 220 people (the patients in Group 1 were administrated Actovegin, the ones in Group 2 – were not). All patients were followed up for 90 days; their condition was assessed by the severity of clinical manifestations of CCI, using special scales and questionnaires.Results and discussion. After 90 days of follow-up, the frequency of complaints of cognitive impairment, sleep disorder, dizziness, fatigue, emotional disorders, and headache in Group 1 was significantly lower than in Group 2 (p<0.05). According to Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), Multidimensional Fatigue Inventory (MFI-20), and Spiegel Sleep Questionnaire (SSQ), the average indicators improved significantly more in Group 1 than in Group 2 (p<0.05). The absence of quality of life impairment and their minimal severity were observed in Group 1 in 77.9%; in Group 2 – in 33.7% (p<0.001). Statistically significant differences between the groups of patients were also observed in relation to emotional state recovery according to the Wakefield Questionnaire and the Spielberger State Trait Anxiety inventory.Conclusion. The observational study demonstrated the efficacy of Actovegin in the treatment of main clinical manifestations of CCI in patients with recent COVID-19 experience.

show abstract

Section: Distribution Of Patients In Accordance With the Improvement unclassified

The role of the new coronavirus infection (COVID-19) in the progression and development of cerebrovascular diseases. A competent choice of pathogenic treatment is the key to success in treatment and prevention. An expert’s view from the ‘red zone’

Ковальчук¹

2021

RJTAO

View full text Add to dashboard Cite

show abstract

“…Результаты данного исследования сопоставимы с данными других авторов, отмечающих эффективность применения данного лекарственного препарата при КН [18][19][20][21]23]. Проведенные зарубежными и российскими авторами исследования показали эффективность Актовегина в отношении улучшения памяти и внимания, психоэмоционального состояния, снижения выраженности астении [22][23][24]. У пациентов после перенесенной коронавирусной инфекции наблюдается прогрессирование КН, сосудистого поражения головного мозга, развитие инсультов [16,17,24].…”

Section: показатели астении по шкале Mfi-20unclassified

“…Широко распространена среди пациентов, перенесших COVID-19, повышенная тревожность, что в значительной степени препятствует проведению оптимальной терапии, реабилитации, а также ухудшает качество жизни паци-ентов; в связи с этим снижение уровня тревожности пациентов на фоне применения Актовегина имеет существенное значение в комплексном их лечении [16,17,21,24].…”

Section: Mfi-20 Fatigue Scoresunclassified

“…Согласно результатам представленного исследования, терапия Актовегином способствует в статистически значимой степени снижению выраженности КН, активизации пациентов, нормализации их сна, значительному улучшению КФ, нормализации эмоционального состояния и повышению качества жизни. Уменьшение выраженности астении является практически значимым аспектом, так как астения часто встречается среди пациентов, перенесших COVID-19, и замедляет возвращение человека к привычной жизнедеятельности [16,17,19,21,24].…”

Section: Mfi-20 Fatigue Scoresunclassified

See 1 more Smart Citation

Actovegin use in patients with cognitive impairment after coronavirus infection (COVID-19)

Kutashov

2021

RJTAO

View full text Add to dashboard Cite

“…Особое внимание обращают на потерю обоняния, вкуса и, что существенно отличает КВИ от гриппа и других респираторных заболеваний, -нарушение тригеминальной чувствительности полости рта [4,8].…”

Section: клиническая симптоматикаunclassified

Olfactory dysfunction in coronavirus disease

Tsepkolenko

Pukhlik

2021

OTORHINOLARYNGOLOGY

View full text Add to dashboard Cite

Olfactory dysfunction may be the only early clinical manifestation in COVID-19 patients with no other significant signs. It is typical of the disease and can be significant for testing. The purpose of the review is to provide guidance to the otorhinolaryngologist in the problem of olfactory dysfunction in SARS-CoV-2 infection. Materials and Methods: The authors analyzed the available clinical data on the problem of olfactory dysfunction in SARS-CoV-2 infection. The data of statistics, clinical symptoms and pathogenesis were studied. Toexplain anosmia in COVID-19 patients, 4 possible mechanisms are considered: nasal congestion / nasal congestion and rhinorrhea; death of olfactory receptor neurons; infiltration of the brain and damage to the olfactorycenters; damage to the supporting cells of the olfactory epithelium. The analysis of clinical cases of patients with prolonged ansomia against the background of COVID-19 was carried out. Conclusions: Smell after COVID-19 in most cases is restored without specific treatment. There are no reports of studies in patients with long-term anosmia.

show abstract

The Nervous System Damage in Covid-19 Patients

Cited by 50 publications

References 206 publications

The role of the new coronavirus infection (COVID-19) in the progression and development of cerebrovascular diseases. A competent choice of pathogenic treatment is the key to success in treatment and prevention. An expert’s view from the ‘red zone’

The role of the new coronavirus infection (COVID-19) in the progression and development of cerebrovascular diseases. A competent choice of pathogenic treatment is the key to success in treatment and prevention. An expert’s view from the ‘red zone’

Actovegin use in patients with cognitive impairment after coronavirus infection (COVID-19)

Olfactory dysfunction in coronavirus disease

Contact Info

Product

Resources

About